The law firm of Wohl & Fruchter LLP is investigating possible violations
of federal securities laws by officers and directors of Intercept
Pharmaceuticals, Inc. (Intercept) (NASDAQ: ICPT).
Intercept is developing a drug, obeticholic acid (OCA), to treat
nonalcoholic steatohepatitis (NASH), a leading cause of cirrhosis and
On January 9, 2014, Intercept announced that the FLINT clinical trial
assessing the safety and efficacy of OCA to treat NASH had been stopped
early based on an interim efficacy analysis showing statistically
significant substantial improvements in measures of liver health (the
primary endpoint of the trial). The trial was sponsored and conducted by
the National Institute of Diabetes & Digestive & Kidney Diseases
(NIDDK), a part of the National Institutes of Health, at eight leading
U.S. academic hepatology centers.
Upon the above news, ICPT stock soaed from a close of $72.39/share on
January 8, 2014, to a close of $445.83 on January 10, 2014.
After the close of the market on January 10, 2014, NIDDK advised the
Wall Street Journal that, in addition to improvements in liver health,
patients taking OCA in the FLINT trial showed "disproportionate lipid
abnormalities" -- including worsened cholesterol levels -- compared with
patients who received a placebo.
Upon the above news, ICPT dropped to $364.36/share in trading on January
Persons with relevant information, and ICPT shareholders with questions
about this investigation, are invited to contact the attorney below, or
our Firm by calling 866.833.6245.
Additional information is available on our website at: http://www.wohlfruchter.com/cases/icpt.
About Wohl & Fruchter
Wohl & Fruchter LLP represents plaintiffs in litigation arising from
fraud and other fiduciary breaches by corporate managers, as well as
other complex litigation matters. Please visit our website, www.wohlfruchter.com,
to learn more about our Firm, or contact one of our partners.
This release may be deemed to constitute attorney advertising.
[ Back To NFVZone's Homepage ]